NIH contract

The company plans to develop a liquid biopsy assay that can identify patients most likely to benefit from treatment with checkpoint inhibitors.

The National Cancer Institute is accepting proposals from groups interested in producing affinity binders for the agency's Antibody Characterization Program.

The program will use transcriptomics, proteomics, lipidomics, and metabolomics to explore immune response.

The NIH award funds a database that catalogs genomic information of clinically, economically, and scientifically important eukaryotic pathogens.

NEW YORK (GenomeWeb) – Moffitt Cancer Center and M2Gen today said they have been awarded a seven-year, $7.3 million contract from the National Heart, Lung, and Blood Institute to coordinate a central laboratory and biorepository for research into myelodysplastic syndromes.

NEW YORK (GenomeWeb) – Cellular Dynamics International today announced a $1.2 million contract from the National Eye Institute to manufacture stem cells for use in the development of a new potential treatment for dry age-related macular degeneration.

NEW YORK (GenomeWeb) – Cofactor Genomics said on Thursday it has won a contract from the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute to identify sites of epigenetic modifications that contribute to cardiovascular disease endpoints.

NEW YORK (GenomeWeb) – Johns Hopkins University today announced a contract from the National Institutes of Health to create a center focused on developing methods, including the use of genomic technologies, to identify and track global influenza outbreaks.

NEW YORK (GenomeWeb News) – Cellular Dynamics International today said that the National Institutes of Health Center for Regenerative Medicine has awarded it a contract for up to $7 million over three years to provide human induced pluripotent stem cell lines and terminally differentiated tissue

NEW YORK (GenomeWeb News) – Genome customization firm Cellectis bioresearch today announced it has won a five-year, $9.5 million contract from the National Institutes of Health for work directed at induced pluripotent stem cells.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.